Remove tag epilepsy
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. Epilepsy affects more than 600,000 people in the UK and for some, seizures can be life-threatening.

Drugs 98
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.